Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24345186 | 0.89 | GNAI3 (0.41) | GPR84FFAR1 | |
| SCHEMBL24040182 | 0.88 | GNAI3 (0.43) | GPR84FFAR1 | |
| SCHEMBL21024634 | 0.86 | GNAI3 (0.42) | GPR84FFAR1CA2 | |
| SCHEMBL19661521 | 0.78 | GPR84 (0.40) | GPR84FFAR1FFAR4ACE2 | |
| SCHEMBL20372808 | 0.77 | ALDH1A1 (0.39) | MAPT | |
| SCHEMBL26465066 | 0.77 | GAA (0.46) | — | |
| SCHEMBL19703560 | 0.76 | GPR84 (0.37) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL19710626 | 0.76 | GPR84 (0.37) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL18615961 | 0.74 | GUSB (0.39) | — | |
| SCHEMBL18922357 | 0.74 | TRPV1 (0.42) | GPR84FFAR1MAPTSIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135538-A1 | P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | CONSTELLATION PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135538-A1 | P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | EP300, KAT2A, HDAC1 | GPR84 3467/4885FFAR1 3151/4885MAPT 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.